Shenzhen Neptunus Bioengineering Co., Ltd. (SZSE:000078) agreed to acquire Shanghai Julikang Medical Technology Group Co., Ltd. from Zhuhai Haiwang Huaxia Equity Investment Fund (L.P.), managed by Shenzhen Huaxia Dexin Fund Management Co., Ltd. for CNY 63 million on April 11, 2022. The Shenzhen Neptunus Bioengineering Co., Ltd. shall pay the transfer price of CNY 63 million to the collection account designated by the seller before April 30, 2022. As on December 31, 2021, Shanghai Julikang Medical Technology Group Co., Ltd. generated the revenue of CNY 89.2956 million, Total assets of CNY 274.1855 million, Net profit -42.4277 million and Net assets of CNY 144.3162 million. Shenzhen Neptunus Bioengineering Co., Ltd.'s board of director approved the transaction.